NCT07634367 clinical trial report covering HSK-39004, Phase 3, endpoints, sponsor, geography, readout timing and development white space.

NCT07631364 clinical trial report covering Disodium edetate, Phase 3, endpoints, sponsor, geography, readout timing and development white space.

NCT07632157 clinical trial report covering Magnesium Carbonate, Phase 3, endpoints, sponsor, geography, readout timing and development white space.

NCT07632898 clinical trial report covering IkT-001Pro, Phase 3, endpoints, sponsor, geography, readout timing and development white space.

CTR20262234 clinical trial report covering Relugolix, Phase 3, endpoints, sponsor, geography, readout timing and development white space.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Nimotuzumab, an antibody targeting EGFR.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Necitumumab, an antibody targeting EGFR.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Panitumumab, an antibody targeting EGFR.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Cetuximab, an antibody targeting EGFR.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Patritumab, an antibody targeting HER3.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Duligotuzumab, a bispecific antibody targeting EGFR/HER3.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Istiratumab, a bispecific antibody targeting IGF-1R/MET.